{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:23:47Z","timestamp":1790285027682,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106692","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:32:23Z","timestamp":1755253943000},"page":"106692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-518X","authenticated-orcid":false,"given":"Arianna","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106692_bib0001","article-title":"A case of late-onset neutropenia in relapsing-remitting multiple sclerosis following Ocrelizumab therapy","volume":"16","author":"Alabdulqader","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.msard.2025.106692_bib0002","first-page":"463","article-title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","volume":"38","author":"Alba Su\u00e1rez","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2025.106692_bib0003","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/jcm8091351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andr\u00e8s","year":"2019","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106692_bib0004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.msard.2025.106692_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106692_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2021","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.msard.2025.106692_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106692_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/13524585231206218","article-title":"Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab","volume":"30","author":"Beigneux","year":"2024","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2025.106692_bib0009","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106692_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106692_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103357","article-title":"Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: prevalence, predicting factors and clinical outcomes","volume":"57","author":"Dinoto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106692_bib0012","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106692_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)","volume":"65","author":"Hammer","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106692_bib0014","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1212\/NXI.0000000000001157","article-title":"Influence of previous disease-modifying drug exposure on T-lymphocyte dynamic in patients with multiple sclerosis treated with Ocrelizumab","volume":"9","author":"Landi","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2025.106692_bib0015","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s10072-021-05379-9","article-title":"Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2025.106692_bib0016","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1007\/s10072-021-05357-1","article-title":"Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient","volume":"42","author":"Marrodan","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106692_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106692_bib0018","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106692_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105147","article-title":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","volume":"81","author":"Pang","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106692_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"issue":"3","key":"10.1016\/j.msard.2025.106692_bib0021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neurol.2021.06.007","article-title":"Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: a prospective study","volume":"178","author":"Rigal","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106692_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106692_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104090","article-title":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: a retrospective case series and a systematic review of reported cases","volume":"68","author":"Rossi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106692_bib0024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.msard.2025.106692_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta","year":"2020","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:17Z","timestamp":1774998917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"alternative-id":["S2211034825004341"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106692","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106692"}}